Login / Signup

The Landscape of PDK1 in Breast Cancer.

Na WangJianjiang FuZhihua LiNingni JiangYanhong ChenJuan Peng
Published in: Cancers (2022)
Given that 3-phosphoinositide-dependent kinase 1 (PDK1) plays a crucial role in the malignant biological behaviors of a wide range of cancers, we review the influence of PDK1 in breast cancer (BC). First, we describe the power of PDK1 in cellular behaviors and characterize the interaction networks of PDK1. Then, we establish the roles of PDK1 in carcinogenesis, growth and survival, metastasis, and chemoresistance in BC cells. More importantly, we sort the current preclinical or clinical trials of PDK1-targeted therapy in BC and find that, even though no selective PDK1 inhibitor is currently available for BC therapy, the combination trials of PDK1-targeted therapy and other agents have provided some benefit. Thus, there is increasing anticipation that PDK1-targeted therapy will have its space in future therapeutic approaches related to BC, and we hope the novel approaches of targeted therapy will be conducive to ameliorating the dismal prognosis of BC patients.
Keyphrases
  • clinical trial
  • end stage renal disease
  • chronic kidney disease
  • induced apoptosis
  • ejection fraction
  • randomized controlled trial
  • bone marrow
  • smoking cessation